Controlled-Release 5HT Agonist Compositions Below Hallucinogenic Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions targeting serotonin pathways for treating mood disorders, such as depression and anxiety, suffer from long onset times, severe side effects, and poor efficacy, including adverse reactions like suicidal thoughts, sexual dysfunction, and weight gain.
Innovation Solution
Development of low-dose pharmaceutical compositions containing 5HT receptor agonists, such as psilocin or psilocybin, administered in controlled release formulations to provide therapeutic effects without adverse side effects, with plasma concentrations maintained below 6 ng/mL to avoid hallucinations and other adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose psilocybin is administered to achieve therapeutic effect, then efficacy is improved, but adverse side effects increase
Solution Approach 1:
The patent changes the dosage parameter from high dose to low dose (0.1-10mg range), and combines it with controlled release mechanism to maintain plasma concentrations below 6ng/mL, thereby achieving therapeutic efficacy while avoiding adverse side effects associated with high doses
Solution Approach 2:
The patent employs controlled release formulations that dynamically regulate the release of psilocybin over time, maintaining plasma concentrations within the therapeutic window (below 6ng/mL) rather than allowing static high concentrations, thus preventing adverse effects while sustaining therapeutic benefit
2Adaptability or versatility
If conventional pharmaceutical compositions are used to treat mood disorders, then treatment coverage is improved, but onset time increases and side effects worsen
Solution Approach 1:
The patent optimizes the dosage parameters to low doses (0.1-10mg) combined with controlled release kinetics, creating a new pharmacokinetic profile that achieves faster onset of action compared to conventional high-dose formulations, while maintaining broad treatment coverage for mood disorders
3Reliability
If psilocybin is administered to treat drug dependence and anxiety, then therapeutic potential is improved, but hallucinations and panic attacks increase
Solution Approach 1:
The patent changes the plasma concentration parameter to remain below 6ng/mL through low dosing and controlled release, which prevents the threshold for hallucinations and panic attacks while preserving the therapeutic potential for treating drug dependence and anxiety disorders
Solution Approach 2:
The controlled release formulation acts as an intermediary mechanism that mediates between the administered psilocybin and the plasma concentration, ensuring that therapeutic levels are maintained without reaching the threshold that triggers adverse psychological effects
Data Source
AI summary
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.